Research in the David Moller Lab focuses on sarcoidosis, a potentially fatal inflammatory disease characterized by tiny clumps of inflammatory cells that scar the lungs, lymph nodes, skin and other major organs. We’re currently involved in a clinical trial related to genomic research in sarcoidosis and a clinical trial related to genomic research in Alpha-1 antitrypsin deficiency. Previously, we led a project that identified a potential protein trigger responsible for sarcoidosis.

Research efforts in the Edward Chen Lab focus on bleomycin-induced pulmonary fibrosis and granulomatous inflammation as well as clinical and translational studies in sarcoidosis. Our studies have included topics such as the etiologies of sarcoidosis, hylleraas hydride binding energy in diatomic electron affinities, and molecular convergence of neurodevelopmental disorders. We have also investigated the use of quantitative mass spectrometric analysis to better understand the mechanisms of phospho-priming and auto-activation of the checkpoint kinase Rad53 in vivo.

The main focus of Dr. Gilotra's research is understanding the pathophysiology and outcomes in inflammatory cardiomyopathies including myocarditis and sarcoidosis, as well as improvement of heart failure patient care through noninvasive hemodynamic monitoring and studying novel strategies to reduce heart failure hospitalizations. Additional investigations involve clinical research in advanced heart failure therapies including heart transplantation and mechanical circulatory support. Dr. Gilotra is the site Principal Investigator for the NIH/NHLBI funded Heart Failure Network trials.